Stockhub

Neuren Pharmaceuticals Limited: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

14 August 2022

13 August 2022

9 August 2022

  • curprev 18:2818:28, 9 August 2022‎ Paris talk contribs‎ 625 bytes +625‎ Created page with "Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Neuren_Pharmaceuticals_Limited’